Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Fariba Soleymanzadeh

Todd Bosanac

Michael Jason Burke

Wang Mao

Joerg Bentzien

Angela Kay Berry

Yunlong Zhang

Darren Todd Disalvo

Yue Shen

Renee M Zindell

Robert Sibley

Thomas Martin Kirrane, Jr

Christopher Ronald Sarko

Roger John Snow

Ronald John Sorcek

Daniel Richard Marshall

Can Mao

Brian Nicholas Cook

Shuang Liang

Sabine K Schlyer

John A Westbrook

Joshua Courtney Horan

Daniel R Goldberg

Neil Moss

Sanxing Sun

Erick Richard Roush Young

Abdelhakim Hammach

Zhonghua Zhang

Zhaoming Xiong

Anne Bettina Eldrup

Donghong Amy Gao

John David Ginn

Xiang Li

Maolin Yu

Pingrong Liu

Ingo Andreas Mugge

Matt Aaron Tschantz

Bryan Patrick McKibben

Xin Guo

Eric T Larson

Jennifer A Kowalski

Gregory Paul Roth

Mark Stephen Ralph

Stephen James Boyer

Antonio J Barbosa

Antonio Jose Del Moral Barbosa, Jr

Ryan Michael Fryer

Lana Louise Smith-Keenan

Tamara Denise Hopkins

Andre White

Eric Thomas Larson

Bryan Patrick Mckibben

Joerg Martin Bentzien

Jr Thomas Martin Kirrane

The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Heteroaromatic compounds as BTK inhibitors

The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use. 

Isoquinolones as BTK inhibitors

The present invention encompasses compounds of the formula (I) wherein the groups R, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

Heterocyclic compounds containing an indole core

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, Rand X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Rho kinase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R-Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Soluble guanylate cyclase activators

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Compounds of the formula (I) wherein R, R, R, R, R, R, W, and Y are as described herein, or a tautomer, prodrug, solvate, or salt thereof. These compounds are useful as inhibitors of Urotensin II and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the interaction of Urotensin II with its receptor, including cardiovascular diseases. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds, and intermediates useful in these processes.

Urotensin II receptor antagonists

Disclosed are benzimidazolone compounds of formulas (I) & (II): wherein R, R, R, R, R, X, L, m, n and t are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds 

Heterocyclic compounds

Growing community of inventors

Danbury, CT, United States of America

Fariba Soleymanzadeh